Actively Recruiting
Prospective Study of Biomarkers from Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft Tissue Sarcomas
Led by University Health Network, Toronto · Updated on 2026-03-04
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a Phase II, single-center study to investigate biomarkers found in bronchoalveolar lavage fluid (BALF) and transbronchial aspirate (TA) in patients with soft tissue sarcoma (STS). The goal is to assess these biomarkers in relation to the amount of metastatic disease present. Samples will be collected during routine bronchoscopy procedures performed as part of standard care at Toronto General Hospital, along with tissue samples from lung metastases and nearby normal lung tissue. During the study, BALF and TA samples will be gathered during routine bronchoscopy, and lung metastases tissue along with adjacent normal lung tissue will be collected during standard care metastasectomy surgery. These samples will be analyzed to identify and quantify inflammatory biomarkers related to neutrophil extracellular traps (NETs) and to understand how these markers correlate with metastatic spread. Participants will undergo bronchoscopy and metastasectomy as part of their usual care, during which samples will be collected. Researchers will measure NET-related inflammatory biomarkers using BALF and TA diagnostic tools over two years. The study will evaluate the relationship between these biomarkers and metastatic burden, with ongoing analysis during this period. The total duration for assessing outcomes is two years, with no specific mention of additional follow-up beyond this timeframe.
CONDITIONS
Brief Title
BAL Fluid Biomarkers in Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Ability to understand and willing to sign a written informed consent document
- Diagnosed with soft tissue sarcoma
- Scheduled for lung lesion resection as part of standard care
You will not qualify if you...
- History of another invasive malignancy except non-melanoma skin cancer or tumors treated with no evidence of disease for at least 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Duration of standard care treatment period
Participants undergo routine bronchoscopy during which bronchoalveolar lavage fluid (BALF) and tracheal aspirate (TA) are collected. They also receive standard of care lung metastasectomy with collection of resected lung metastases and adjacent normal tissue.
1 routine bronchoscopy visit and 1 lung metastasectomy surgery visit
Trial Site Locations
Total: 1 location
1
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
D
David Shultz
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here